← All trials
NCT04162522
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2019
- Primary completion
- Dec 1, 2021
- Completion date
- Dec 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- Unity Health TorontoCollaborator
- McGill UniversityCollaborator
- McMaster UniversityCollaborator
- Queen's University, BelfastCollaborator
- Simon Fraser UniversityCollaborator
- University of MichiganCollaborator
- University of OttawaCollaborator
- University of TorontoCollaborator
- University of TorontoCollaborator
- University of TorontoOverall official - principal investigator
- University of TorontoReponsible party - principal investigator
- Dalhousie UniversityCollaborator
- University of British ColumbiaCollaborator
- University of CalgaryCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.